ra 642 has been researched along with Alloxan Diabetes in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de la Cruz, JP; García-Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
2 other study(ies) available for ra 642 and Alloxan Diabetes
Article | Year |
---|---|
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Cataract; Diabetes Mellitus, Experimental; Dipyridamole; Lens, Crystalline; Lipid Peroxidation; Male; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Superoxides | 1994 |
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epoprostenol; Male; Mopidamol; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Pyrimidines; Rats; Rats, Wistar; Thromboxanes | 1996 |